General pharmaceutical principles for handling lyophilized peptides apply to ipamorelin. However, no independently published, peer-reviewed stability study specific to this compound was identified in the scientific literature reviewed for this article. This means that specific storage duration numbers circulating commercially reflect manufacturer or vendor convention, rather than confirmed, independent research. This article carefully maintains that distinction throughout.
How to store Ipamorelin
As a matter of general pharmaceutical peptide science, ipamorelin, like other peptides, is typically supplied as a lyophilized powder. This dry state is generally more chemically stable over time than the same peptide already dissolved in a liquid. Standard practice for lyophilized peptides broadly, consistent across pharmaceutical and laboratory guidelines, calls for storing the unopened powder in a cool, dry, dark environment, protected from light and moisture. Freezer storage, around -20°C, is commonly recommended for maximizing the shelf life of the unreconstituted powder for extended periods.
Once reconstituted into liquid form, general pharmaceutical convention, derived from well-researched comparable products such as multi-dose insulin, dictates that the resultant solution should be refrigerated, commonly within the range of 2–8°C, rather than stored at room temperature. Dissolved peptides are understood to be more susceptible to degradation from heat, light, and time than their lyophilized counterparts.
Regarding freezing reconstituted solution specifically, general laboratory handling guidelines for peptides commonly advise against repeated freeze-thaw cycling. The physical process of freezing and thawing liquids can potentially disrupt the peptide's structure through ice crystal formation and mechanical stress. This is a widely applicable precaution for peptides handled as liquids—not a discovery from a dedicated study of ipamorelin freeze-thaw.
It's worth being direct that these storage practices reflect general, well-established principles applied consistently across the field of peptide handling, rather than findings from an independently published study measuring the specific degradation rate of ipamorelin under controlled conditions.
Regarding the separate question of taking ipamorelin on an empty stomach, this pertains to timing, not storage. As discussed in an earlier article in this series, the general reasoning is that rising blood glucose and insulin levels post-meal are known in general endocrinology to suppress growth hormone release. This is the likely basis for the common suggestion to fast, although it has not been directly tested as a dedicated study of fasted versus fed states for ipamorelin itself.
How long does Ipamorelin last in the refrigerator?
This is an area requiring the greatest caution, as the gap between commercial claims and independently verified science is widest here. Commercial and laboratory sources commonly describe reconstituted ipamorelin as remaining stable under refrigeration for periods often cited somewhere between two and four weeks. Different sources offer slightly different specific numbers within this general range. These numbers should be understood as manufacturer or seller guidelines and general industry convention—not as findings from an independently conducted, peer-reviewed stability study. No such published study measuring the actual rate of chemical degradation of ipamorelin over time after reconstitution has been identified in the literature reviewed for this article.
This is an important distinction to remember. A vendor stating a shelf life on a product page is not the same as a controlled analytical chemistry study measuring how much intact, active peptide remains at specific time points after reconstitution. This latter type of independent verification does not appear to exist in the published record specifically for ipamorelin yet.
Regarding how long unopened, unreconstituted ipamorelin powder remains viable, similarly no independently published stability studies have been identified. General peptide science would suggest, however, that the dry powder form remains stable significantly longer than a reconstituted solution, consistent with the general principle outlined above.
Regarding how long ipamorelin can tolerate being unrefrigerated, whether as a powder or after reconstitution, no dedicated stability data exists in the peer-reviewed literature reviewed here. Any specific number of hours or days offered elsewhere should be treated as informal guidance, not as confirmed science.
It is worth separately and clearly addressing another commonly confused question. How long does ipamorelin remain active in the body after a dose? This is a separate pharmacokinetic question with a true, directly available answer. Human studies have shown that ipamorelin has a short terminal half-life of about two hours. Its growth hormone-stimulating effect peaks around 40 minutes after administration and returns to baseline within approximately six hours [1].
This describes how quickly a compound is cleared from the bloodstream after use. This is an entirely separate matter from how long a reconstituted vial remains chemically stable for future use.
Limitations of current evidence
The general storage principles described in this article are well-established and broadly applicable to lyophilized peptides as a category. This includes why peptides are supplied freeze-dried, why refrigeration is recommended for reconstituted solutions, and why repeated freeze-thaw cycling is generally discouraged.
What remains truly absent in the reviewed literature is dedicated, independently published stability research measuring specific degradation rates for ipamorelin, whether in powder form or reconstituted. This means the commercially cited two-to-four-week figures should be understood as manufacturer or vendor claims, rather than confirmed, independent scientific findings.
Disclaimer
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use, and no independently published, peer-reviewed stability or shelf-life study specific to this compound has been identified for this article. It is not manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. The storage information provided herein reflects general, well-established principles for the pharmaceutical handling of peptides and is intended for educational purposes only. It does not constitute manufacturer-verified stability data, nor is it medical or laboratory advice. This article is provided for general educational and informational purposes only, reflects the state of published scientific literature at the time of writing, and nothing herein should be interpreted as a recommendation to use, source, or administer ipamorelin.
References
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402